First Shipment of RiVive(TM) Brings Life-saving Over-The-Counter Naloxone Nasal Spray One Step Closer to Those Who Need It Most
Pittsburgh, Pennsylvania--(Newsfile Corp. - Decem
2023-12-18 9:00 AM EST
FDA Approval of RiVive(TM) Is a Critical Milestone in Making Emergency Treatment of Opioid Overdose More Widely Available
Pittsburgh, Pennsylvania--(Newsfile Corp. - July 28, 2023) - Harm Reduction Therapeutics (HRT), Inc., a nonprofit pharmaceutical company, announced today that FDA has approved OTC RiVive™ (naloxone HCl nasal spray 3 mg) for the emergency treatment of opioid overdose. This critical milestone will help prevent opioid overdose deaths by making free or low-cost over-the-counter (OTC) naloxone nasal spray available to everyone in the United States. "We are grate
2023-07-28 1:45 PM EDT